Clinical outcomes among cardiogenic shock patients supported with high-capacity Impella axial flow pumps: A report from the Cardiogenic Shock Working Group.
Justin FriedMaryjane FarrManreet KanwarNir UrielJaime Hernandez-MontfortVanessa BlumerSong LiShashank S SinhaA Reshad GaranBorui LiShelley HallGavin W HickeyClaudius MahrSandeep NathanAndrew SchwartzmanJu KimVan-Khue TonOleg A VishnevskyEsther VorovichJacob AbrahamElric ZweckMaya GuglinSaraschandra VallabhajosyulaRachna KatariaKarol D WalecPeter ZazzaliQiuyue KongPaavani SangalDaniel BurkhoffNavin K KapurPublished in: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2024)
High capacity Impella heart pumps are capable of provide up to 5.5 liter/min of flow while upper body surgical placement allows for ambulation. Patients with advanced cardiogenic shock from acute myocardial infarction or heart failure requiring temporary mechanical circulatory support may benefit from upfront use of Impella 5.5 to improve overall survival, including native heart recovery or successful bridge to durable left ventricular assist device surgery or heart transplantation.
Keyphrases
- left ventricular assist device
- heart failure
- acute myocardial infarction
- extracorporeal membrane oxygenation
- end stage renal disease
- ejection fraction
- atrial fibrillation
- left ventricular
- newly diagnosed
- minimally invasive
- chronic kidney disease
- percutaneous coronary intervention
- patient reported outcomes
- acute heart failure